BioGaia AB (publ) (BIOG_B) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hi, this is Teresa Agnew, CEO of BioGaia, and we are here to report on our Q2 2025 results. For Q2, our sales were 405 million SEC, which represents growth of 5%. That was mainly due to higher sales in Americas, specifically North America and Asia Pacific. We did have growth of 13.2% when you exclude currency effects for the quarter. Sales in Europe, Middle East, Africa decreased by 1%. In Asia Pacific, sales increased by 15%. And in the Americas, sales increased by 5%. Our EBIT was 108 million SEC, which was a decrease of 20%. And our EBIT margin for the quarter was 27%. We also, over the period of Q2, announced that we are establishing direct sales in the Netherlands for the first time. This is a market in Europe where we never had bio Gaia sales. So this is a first for us where we have launched our business online. And I can talk about that a little bit more. I also wanted to mention first half sales were 771 million sec, which was growth of 2%. And that is growth of 5%, excluding the currency effects. Some of our launches over the quarter, you can see listed here where we launched our BioGaia Gastros product. We launched Protectus Drops in Jordan, and we also launched a new product. So we had our first launch last year in Finland of BioGaia Gastros Pure Action. And we have continued to roll out that product in Q2 of this year in Sweden, Poland, and Hungary. And we will continue for the remainder of the year to roll that product out in even more markets. In terms of key events, we did announce that we were establishing direct sales in the Netherlands, and this was through Amazon and Bull. These are two of the leading online marketplaces in the Netherlands, and this launch is going very well. Actually, the results have surpassed our expectations. Also on May 30th, ...